Blunt Business speaks with Joel Latham, CEO of Incannex Healthcare (NASDAQ: IXHL), a clinical-stage biopharmaceutical company pioneering the use of proprietary combination medicines.
Latham breaks down their strategy of fusing synthetic cannabinoids and well-characterized active drug components to target chronic conditions with significant unmet needs, emphasizing a robust intellectual property position and synergistic drug action.